Requip

How to order Requip

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Requip on Prescriptsy

Requip is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Requip is the brand name for ropinirole, a non-ergot dopamine agonist used to treat the motor symptoms of Parkinson's disease and the symptoms of moderate to severe restless legs syndrome (RLS).

Ropinirole works by directly stimulating dopamine D2 and D3 receptors in the brain, compensating for the dopamine deficiency that underlies both conditions.

Requip is available as immediate-release tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg, 5 mg) and prolonged-release tablets (Requip XL, 2 mg, 4 mg, 8 mg).

It is a prescription-only medicine (POM) in the UK, originally developed by GlaxoSmithKline.

Parkinson's disease is the second most common neurodegenerative disorder, affecting approximately 153,000 people in the UK.

It results from the progressive loss of dopaminergic neurones in the substantia nigra pars compacta of the midbrain, leading to a deficit of dopamine in the basal ganglia.

The cardinal motor features are bradykinesia (slowness of movement), rigidity, resting tremor, and postural instability.

Non-motor symptoms, including cognitive impairment, depression, sleep disturbance, autonomic dysfunction, and pain, are increasingly recognised as major contributors to disability and reduced quality of life.

Restless legs syndrome is one of the most common neurological conditions, with a prevalence of approximately 5% to 10% in the general population.

This page provides a detailed clinical guide to Requip, covering how it works, dosage instructions, side effects, important safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about Requip

Before reading further, please note these essential safety points.

• Dopamine agonists, including ropinirole, can cause impulse control disorders such as compulsive gambling, hypersexuality, compulsive spending, and binge eating. Patients and carers must be informed of this risk before starting treatment.
• Ropinirole may cause sudden onset of sleep, sometimes without warning. Patients must not drive if affected and should notify the DVLA.
• Do not stop ropinirole abruptly. Sudden withdrawal can cause a severe withdrawal syndrome. Your prescriber will taper the dose gradually.
• Report hallucinations, confusion, or any new behavioural changes to your prescriber promptly.
• Rise slowly from sitting or lying positions to reduce dizziness from postural hypotension.

Understanding Parkinson's disease

Parkinson's disease is a chronic, progressive neurodegenerative condition.

The pathological hallmark is the loss of dopamine-producing neurones in the substantia nigra, accompanied by the presence of Lewy bodies (intracellular aggregates of alpha-synuclein protein) in surviving neurones.

By the time motor symptoms appear, approximately 50% to 80% of striatal dopamine has already been lost.

The resulting dopamine deficit disrupts the balance of excitatory and inhibitory signalling within the basal ganglia circuitry, leading to the characteristic motor symptoms: bradykinesia, rigidity, rest tremor (typically asymmetric), and later, postural instability.

The management of Parkinson's disease focuses on restoring dopaminergic function. Levodopa (combined with a dopa decarboxylase inhibitor) remains the most effective symptomatic treatment.

However, long-term levodopa use is associated with motor complications, including wearing-off fluctuations and dyskinesias.

Dopamine agonists such as ropinirole are used either as initial monotherapy (particularly in younger patients, where delaying levodopa may reduce the risk of early motor complications) or as adjunctive therapy to levodopa in later disease stages.

NICE guideline NG71 (Parkinson's disease in adults) provides comprehensive management recommendations.

Understanding restless legs syndrome

Restless legs syndrome (RLS), also called Willis-Ekbom disease, is a neurological condition characterised by an irresistible urge to move the legs, usually accompanied by uncomfortable or unpleasant sensations described as crawling, tingling, aching, or pulling.

The symptoms occur predominantly at rest, are worse in the evening and at night, and are partially or fully relieved by movement.

RLS often disrupts sleep and significantly impairs quality of life.

Primary (idiopathic) RLS has a genetic component and is believed to involve dysfunction of the dopaminergic system, particularly in the hypothalamic A11 diencephalospinal pathway.

Secondary RLS can be caused by iron deficiency, renal failure, pregnancy, and certain medicines (including antidepressants and antipsychotics).

NICE CKS on restless legs syndrome recommends that initial management should address any underlying cause (such as iron deficiency), followed by non-pharmacological measures.

If pharmacological treatment is needed, a dopamine agonist (ropinirole or pramipexole) or an alpha-2-delta ligand (gabapentin or pregabalin) is recommended.

Ropinirole is one of only two medicines licensed in the UK specifically for the treatment of moderate to severe RLS.

How Requip works

Ropinirole is a non-ergoline dopamine agonist with high selectivity for the D2 subfamily of dopamine receptors (D2, D3, and D4), with particularly strong affinity for the D3 receptor.

In Parkinson's disease, it stimulates dopamine receptors in the striatum directly, bypassing the need for conversion to dopamine by the degenerating dopaminergic neurones.

This provides symptomatic relief of bradykinesia, rigidity, and tremor.

The D3 receptor selectivity may contribute to effects on mood, motivation, and reward pathways, which is relevant to both the therapeutic effects and the risk of impulse control disorders.

In restless legs syndrome, ropinirole is thought to act on dopamine receptors in the spinal cord and hypothalamus, modulating sensory processing and motor output.

The exact mechanism by which dopamine agonists relieve RLS symptoms is not fully elucidated, but the rapid therapeutic response supports a central dopaminergic mechanism.

Unlike ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), ropinirole does not carry the risk of fibrotic complications, including cardiac valvular fibrosis, retroperitoneal fibrosis, or pulmonary fibrosis.

This represents a significant safety advantage and is one reason why non-ergot dopamine agonists are preferred in current UK practice.

NICE NG71 recommends that ergot-derived dopamine agonists should not be used as first-line treatment for Parkinson's disease.

Clinical evidence for Requip

In Parkinson's disease, ropinirole has been studied as both monotherapy and adjunctive therapy.

The REAL-PET study demonstrated that ropinirole monotherapy was associated with a slower rate of decline in dopamine transporter binding (a marker of dopaminergic neuronal integrity) compared with levodopa over 2 years, although the clinical significance of this finding remains debated.

The 056 study showed that ropinirole monotherapy reduced the risk of developing levodopa-induced dyskinesia over 5 years compared with levodopa alone.

As adjunctive therapy, ropinirole has been shown to reduce off-time and improve motor function in patients with motor fluctuations on levodopa.

In restless legs syndrome, pivotal trials including the TREAT RLS 1 and 2 studies demonstrated significant improvements in the International Restless Legs Syndrome Study Group (IRLS) rating scale and Clinical Global Impression scores with ropinirole 0.25 to 4 mg daily compared with placebo.

The therapeutic response was generally seen within 1 to 2 weeks.

Augmentation (paradoxical worsening of symptoms during treatment) is a recognised long-term concern with dopamine agonist therapy for RLS, occurring in approximately 5% to 10% of patients per year.

Requip compared with other dopamine agonists

The main non-ergot dopamine agonists used in the UK are ropinirole, pramipexole, and rotigotine (transdermal patch).

All three are recommended by NICE for Parkinson's disease and have broadly similar efficacy. Pramipexole (Mirapexin) has a slightly different receptor binding profile with higher D3 selectivity.

Rotigotine (Neupro) is delivered as a daily patch, which may improve adherence and provide more stable plasma levels.

The choice between these agents is based on individual response, tolerability, formulation preference, and side-effect profile.

All non-ergot dopamine agonists share the class-wide risks of impulse control disorders, sudden onset of sleep, and postural hypotension.

Dosage and administration

Ropinirole must be started at a low dose and increased gradually over several weeks to minimise side effects, particularly nausea and dizziness.

For Parkinson's disease, the starting dose is 0.25 mg three times daily (or 2 mg once daily for Requip XL), with gradual increases to the effective dose range of 3 to 24 mg per day.

For RLS, the starting dose is 0.25 mg once daily before bedtime, titrated to a maximum of 4 mg daily. Always take ropinirole with food.

Do not crush or chew prolonged-release tablets.

Side effects of Requip

Common side effects

Nausea, vomiting, and dizziness are the most frequently reported side effects and are most common during dose titration. They usually improve with continued treatment. Somnolence (excessive sleepiness) is common and may affect the ability to drive safely.

Impulse control disorders

This is one of the most clinically important adverse effects of dopamine agonist therapy. Pathological gambling, hypersexuality, compulsive spending, binge eating, and punding have been reported.

These behaviours can have devastating personal, financial, and legal consequences. The MHRA has issued Drug Safety Updates and an enhanced warning about this risk.

Patients and carers should be informed before treatment begins and monitored at every review.

If an ICD develops, the dopamine agonist dose should be reduced or the medicine stopped.

Sleep disturbance

Sudden onset of sleep episodes, sometimes without preceding drowsiness, is a serious safety concern.

Patients must be warned about this risk, advised not to drive if affected, and informed of their obligation to notify the DVLA.

Excessive daytime sleepiness should prompt a review of the ropinirole dose and consideration of contributing factors such as other sedating medicines or sleep disorders.

When to seek medical advice

Contact your prescriber or Parkinson's nurse if you experience hallucinations, confusion, impulse control behaviours, excessive sleepiness, sudden sleep episodes, or severe dizziness.

Call 999 if you lose consciousness or have a fall with injury. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Impulse control disorder screening

Before starting ropinirole, your prescriber should ask about any history of addictive or impulsive behaviours.

At each follow-up appointment, both the patient and their carer (if applicable) should be asked specifically about gambling, spending, sexual behaviour, and eating patterns.

Early detection allows prompt dose reduction or treatment change.

Dopamine agonist withdrawal syndrome

Abrupt withdrawal of ropinirole may cause anxiety, depression, panic attacks, insomnia, irritability, pain, fatigue, sweating, and apathy. In severe cases, symptoms can be disabling. Ropinirole should always be tapered gradually under medical supervision, not stopped abruptly.

Drug interactions

CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) can increase ropinirole levels. CYP1A2 inducers (tobacco smoking) can decrease levels.

If a patient stops smoking during treatment, ropinirole levels may rise and dose adjustment may be needed.

Antipsychotics (dopamine antagonists) oppose the action of ropinirole and should generally be avoided. Sedating medicines and alcohol may worsen somnolence.

Living well with Parkinson's disease

Medication is a central component of Parkinson's management, but a multidisciplinary approach delivers the best outcomes. Physiotherapy helps maintain mobility, balance, and strength.

Occupational therapy supports daily activities and home safety. Speech and language therapy addresses voice and swallowing difficulties.

Regular exercise, including walking, tai chi, dance, and cycling, has been shown to improve motor function and quality of life.

Parkinson's UK provides comprehensive information, support groups, and a helpline for people with Parkinson's and their families.

How to get Requip in the UK

Requip and generic ropinirole are available on NHS prescription from your GP, neurologist, or Parkinson's disease specialist.

Generic ropinirole is routinely prescribed and is significantly less expensive than the branded product.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Prepayment certificates are available for patients who need multiple prescription items.

Sources

• Requip, Summary of Product Characteristics (EMC)
• Ropinirole, British National Formulary (BNF)
• NICE NG71: Parkinson's disease in adults
• Restless legs syndrome, NICE CKS
• Parkinson's disease, NHS
• Parkinson's UK
• MHRA Yellow Card Scheme